Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 17

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 17
---
 announced at the Annual Meeting. The Company will publish final results in a Current Report on Form 8 -Kthat the Company expects to file with the U.S. Securities and Exchange Commission (the “SEC”) within four business days after the Annual Meeting. If final voting results are not available at that time, the Company will disclose the preliminary results in a Current Report on Form 8 -Kand, within four business days after the final voting results are known to us, file an amended Current Report on Form 8 -Kto disclose the final voting results. How and when did CERo become a public company? On June 4, 2023, PBAX entered into a Business Combination Agreement with Legacy CERo and Merger Sub, pursuant to which Merger Sub merged with and into Legacy CERo, with Legacy CERo surviving as a wholly -ownedsubsidiary of PBAX. In connection with the consummation of the Business Combination on February 14, 2024, PBAX changed its corporate name to “CERo Therapeutics Holdings, Inc.” At the time of the Business Combination, PBAX was publicly traded, having closed its initial public offering on October 8, 2021. What is “Legacy CERo”? References in this proxy statement to “Legacy CERo” refer to CERo Therapeutics, Inc. prior to the closing of the Business Combination. Who can provide me with additional information and help answer my questions? If you would like additional copies, without charge, of this proxy statement or if you have questions about the proposals being considered at the Annual Meeting, including the procedures for voting your shares, you should contact Okapi Partners, LLC, at (877) 566 -1922(toll free) or by e -mailatinfo@okapipartners.com. 6 PROPOSAL NO. 1: REVERSE STOCK SPLIT PROPOSAL Overview The Board has approved and declared advisable an amendment to our Certificate of Incorporation to combine the outstanding shares of our Common Stock into a lesser number of outstanding shares, a so -called“reverse stock split.” If approved by the stockholders as proposed, the Board would have the sole discretion to effect the Reverse Stock Split at any time after approval of such amendment and no later than the one year anniversary of such approval and to fix the specific ratio for the Reverse Stock Split, provided that the ratio would be not less than one -for-twoand not more than one -for-twenty